|
Total 326 Docetaxel
Patents
(Data from US
Patent & Trademark Office)
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 326 /
No. 101 - 200 Docetaxel Patents:
|
PAT. NO. |
|
Title |
| 101 |
6,395,300 |
 |
Porous
drug matrices and methods of manufacture thereof |
| 102 |
6,392,055 |
|
Synthesis
and biological evaluation of analogs of the antimitotic marine
natural product curacin A |
| 103 |
6,388,131 |
|
Benzene
compounds as antiproliferative and cholesterol lowering agents |
| 104 |
6,387,903 |
|
Inhibitors
of prenyl-protein transferase |
| 105 |
6,387,902 |
|
Phenazine
compounds, methods and pharmaceutical compositions for inhibiting
PARP |
| 106 |
6,383,522 |
|
Toxicity
reduced composition containing an anti-neoplastic agent and a shark
cartilage extract |
| 107 |
6,380,405 |
|
Taxane
prodrugs |
| 108 |
6,380,232 |
|
Benzimidazole
urea derivatives, and pharmaceutical compositions and unit dosages
thereof |
| 109 |
6,380,228 |
|
Inhibitors
of prenyl-protein transferase |
| 110 |
6,380,211 |
|
Alkoxy-substituted
compounds, methods, and compositions for inhibiting PARP activity |
| 111 |
6,380,193 |
|
Fused
tricyclic compounds, methods and compositions for inhibiting PARP
activity |
| 112 |
6,379,382 |
|
Stent
having cover with drug delivery capability |
| 113 |
6,379,381 |
|
Porous
prosthesis and a method of depositing substances into the pores |
| 114 |
6,376,644 |
|
Biodegradable
polymers chain-extended by phosphates, compositions, articles and
methods for making and using the same |
| 115 |
6,376,525 |
|
Method
and composition for treating cancer using cellular organelle
crystallizing agents |
| 116 |
6,376,514 |
|
Substituted
six-membered heterocyclic compounds useful for treating multidrug
resistance and compositions and methods thereof |
| 117 |
6,376,496 |
|
Inhibitors
of prenyl-protein transferase |
| 118 |
6,372,738 |
|
Cytotoxic
agents comprising taxanes and their therapeutic use |
| 119 |
6,372,249 |
|
Senscent
cell-derived inhibitors of DNA synthesis |
| 120 |
6,369,244 |
|
C13
amido substituted taxane derivatives and pharmaceutical compositions
containing them |
| 121 |
6,369,096 |
|
Benzyloxy
prodigiosine compounds |
| 122 |
6,365,627 |
|
Method
for treating a patient with neoplasia by treatment with a paclitaxel
derivative |
| 123 |
6,362,217 |
|
Taxane
anticancer agents |
| 124 |
6,362,207 |
|
Methods
of treating viral infections with benzimidazoles |
| 125 |
6,359,154 |
|
C7
carbamoyloxy substituted taxanes |
| 126 |
6,358,996 |
|
Stable
isotope labeling of paclitaxel |
| 127 |
6,358,985 |
|
Inhibitors
of prenyl-protein transferase |
| 128 |
6,358,956 |
|
Inhibitors
of prenyl-protein transferase |
| 129 |
6,355,643 |
|
Inhibitors
of prenyl-protein transferase |
| 130 |
6,350,755 |
|
Inhibitors
of prenyl-protein transferase |
| 131 |
6,350,464 |
|
Methods
for treating ovarian cancer, poly (phosphoester) compositions, and
biodegradable articles for same |
| 132 |
6,348,215 |
|
Stabilization
of taxane-containing dispersed systems |
| 133 |
6,346,110 |
|
Chamber
for applying therapeutic substances to an implantable device |
| 134 |
6,342,520 |
|
Locally
injectable chemotherapeutics |
| 135 |
6,340,701 |
|
Cytotoxic
agents comprising taxanes and their therapeutic use |
| 136 |
6,339,164 |
|
C2
substituted phenyl taxane derivatives and pharmaceutical
compositions containing them |
| 137 |
6,335,343 |
|
Inhibitors
of prenyl-protein transferase |
| 138 |
6,333,348 |
|
Use
of docetaxel for treating cancers |
| 139 |
6,333,347 |
|
Intrapericardial
delivery of anti-microtubule agents |
| 140 |
6,333,335 |
|
Phenyl-protein
transferase inhibitors |
| 141 |
6,329,376 |
|
Inhibitors
of prenyl-protein transferase |
| 142 |
6,323,205 |
|
Combinations
of 10-propargyl-10-deazaaminopterin and taxols and methods of using
same in the treatment of tumors |
| 143 |
6,322,797 |
|
Biodegradable
terephthalate polyester-poly (phosphate) polymers, compositions,
articles, and methods for making and using the same |
| 144 |
6,319,923 |
|
Method
of treating a tumor |
| 145 |
6,319,682 |
|
Methods
and systems for assessing biological materials using optical and
spectroscopic detection techniques |
| 146 |
6,316,522 |
|
Bioresorbable
hydrogel compositions for implantable prostheses |
| 147 |
6,316,436 |
|
Inhibitors
of prenyl-protein transferase |
| 148 |
6,312,957 |
|
Genetic
modification of primate hemopoietic repopulating stem cells |
| 149 |
6,310,039 |
|
Antineoplastic
conjugates of transferrin, albumin and polyethylene glycol |
| 150 |
6,307,088 |
|
Synthesis
of taxol, taxol analogs and their intermediates with variable A-ring
side chain structures and compositions thereof |
| 151 |
6,307,071 |
 |
Synthesis
of paclitaxel from baccatin III by protection of the 7-hydroxyl of
baccatin III using a strong base and an electrophile |
| 152 |
6,306,893 |
|
Taxoid
derivatives and process for producing the same |
| 153 |
6,297,239 |
|
Inhibitors
of prenyl-protein transferase |
| 154 |
6,291,684 |
|
Process
for the preparation of aziridinyl epothilones from oxiranyl
epothilones |
| 155 |
6,291,504 |
|
Acylsemicarbazides
and their uses |
| 156 |
6,291,425 |
|
Compounds,
methods and pharmaceutical compositions for treating cellular
damage, such as neural or cardiovascular tissue damage |
| 157 |
6,290,957 |
|
Anti-IgE
antibodies and method of improving polypeptides |
| 158 |
6,288,040 |
|
Medicament
excipient particles for tissue-specific application of a medicament |
| 159 |
6,287,628 |
|
Porous
prosthesis and a method of depositing substances into the pores |
| 160 |
6,287,602 |
|
Treatment
of oncologic tumors with an injectable formulation of a Golgi
apparatus disturbing agent |
| 161 |
6,284,923 |
|
Substituted
benzene compounds as antiproliferative and cholesterol lowering
action |
| 162 |
6,284,755 |
|
Inhibitors
of prenyl-protein transferase |
| 163 |
6,284,267 |
|
Amphiphilic
materials and liposome formulations thereof |
| 164 |
6,274,635 |
|
Alkylated
resorcinol derivatives for the treatment of immune diseases |
| 165 |
6,267,957 |
|
Attaching
agents to tissue with transglutaminase and a transglutaminase
substrate |
| 166 |
6,265,587 |
|
Intermediary
compounds for the hemisynthesis of taxanes and preparation processes
therefor |
| 167 |
6,262,107 |
|
Water
soluble paclitaxel prodrugs |
| 168 |
6,262,096 |
|
Aminothiazole
inhibitors of cyclin dependent kinases |
| 169 |
6,262,094 |
|
C-21
modified epothilones |
| 170 |
6,262,054 |
|
Combination
therapy method for treating breast cancer using edatrexate |
| 171 |
6,262,032 |
|
Method
of destroying hyperproliferative cells by combined p53 and taxoid
treatment |
| 172 |
6,261,795 |
|
Radiation
resistance assay for predicting treatment response and clinical
outcome |
| 173 |
6,254,632 |
|
Implantable
medical device having protruding surface structures for drug
delivery and cover attachment |
| 174 |
6,251,682 |
|
Method
and markers for prognosticating efficacy of anticancer agents |
| 175 |
6,245,805 |
|
Method,
compositions and kits for increasing the oral bioavailability of
pharmaceutical agents |
| 176 |
6,242,478 |
|
Five
member ring sulfenate esters and thiosulfinate esters |
| 177 |
6,239,167 |
|
Antitumor
compositions containing taxane derivatives |
| 178 |
6,235,776 |
|
Method
for treating a patient with neoplasia by treatment with a paclitaxel
derivative |
| 179 |
6,232,477 |
|
Methods
of preparing new taxoids and pharmaceutical compositions containing
them |
| 180 |
6,225,325 |
|
Use
of alkylated iminosugars to treat multidrug resistance |
| 181 |
6,222,053 |
|
Semi-synthesis
of a protected baccatin III compound |
| 182 |
6,218,144 |
|
Costal2
genes and their uses |
| 183 |
6,214,880 |
|
Arylsulfonanilide
ureas |
| 184 |
6,214,860 |
|
Synergistic
antitumor composition containing a naphthalensulphonic acid
derivative |
| 185 |
6,214,852 |
|
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide
inhibitors of cyclin dependent kinases |
| 186 |
6,211,167 |
|
Arylsulfonanilide
phosphates |
| 187 |
6,210,436 |
|
Implantable
members for receiving therapeutically useful compositions |
| 188 |
6,207,660 |
|
Texaphyrin
conjugates and uses thereof |
| 189 |
6,203,551 |
|
Chamber
for applying therapeutic substances to an implant device |
| 190 |
6,201,020 |
|
Ortho-diphenol
compounds, methods and pharmaceutical compositions for inhibiting
parp |
| 191 |
6,197,785 |
|
Alkoxy-substituted
compounds, methods, and compositions for inhibiting PARP activity |
| 192 |
6,197,051 |
|
Polycarbonate-polyurethane
dispersions for thromobo-resistant coatings |
| 193 |
6,191,290 |
|
Taxane
derivatives for targeted therapy of cancer |
| 194 |
6,191,170 |
|
Benzenesulfonamides
and benzamides as therapeutic agents |
| 195 |
6,180,802 |
|
Method
for selective protection of baccatin derivatives and its application
to taxane synthesis |
| 196 |
6,179,817 |
|
Hybrid
coating for medical devices |
| 197 |
6,177,460 |
|
Method
of treatment for cancer or viral infections |
| 198 |
6,172,076 |
|
Inhibitors
of prenyl-protein transferase |
| 199 |
6,166,173 |
|
Biodegradable
polymers chain-extended by phosphates, compositions, articles and
methods for making and using the same |
| 200 |
6,156,746 |
|
1,2,5-benzothiadiazepine-1,1-dioxides
with n-2 imidazolylalkyl substituents |
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 326 /
|
